Skip to main content
. Author manuscript; available in PMC: 2025 Jun 1.
Published in final edited form as: J Clin Oncol. 2024 Mar 8;42(16):1890–1902. doi: 10.1200/JCO.23.01507

TABLE 3.

Prognostic Effect of HER2 Expression in the NanoString Cohort

Prognostic Effect
HER2 (NanoString) Model 1a Model 2b Model 3c
HRf (95% CI)e P HRf (95% CI)e P HRf (95% CI)e P
OS
.0014 d .0003 d .0027 d
 Above median 1.000 (0.997 to 1.004) .8883 1.001 (0.998 to 1.005) .4725 1.002 (0.998 to 1.005) .3075
 Below median 0.826 (0.745 to 0.916) .0003 0.803 (0.722 to 0.893) <.0001 0.832 (0.747 to 0.926) .0007
PFS
.0001 d .0001 d .0007 d
 Above median 1.001 (0.998 to 1.004) .5036 1.001 (0.998 to 1.004) .4851 1.002 (0.999 to 1.005) .2762
 Below median 0.809 (0.733 to 0.892) <.0001 0.806 (0.728 to 0.891) <.0001 0.822 (0.743 to 0.910) .0002
Overall response
.0399 d .0545 d .1707d
 Above median 1.000 (0.994 to 1.006) .9772 0.999 (0.993 to 1.005) .7902 0.998 (0.992 to 1.005) .5822
 Below median 1.274 (1.055 to 1.537) .0117 1.267 (1.045 to 1.535) .0159 1.204 (0.989 to 1.467) .0648

NOTE. Bold entries identify significant P values.

Abbreviations: HR, hazard ratio; MSI, microsatellite instability; OS, overall survival; PFS, progression-free survival; PS, performance status.

a

Model includes NanoString (linear spline with one knot at median).

b

Model additionally includes arm, age, chemotherapy, previous adjuvant therapy, previous radiation therapy, race, sex, number of metastatic sites, PS, tumor sidedness, and synchronous/metachronous.

c

Model additionally includes BRAF, RAS, and MSI.

d

Test to evaluate the prognostic effect of HER2 expression by comparing a model with HER2 expression with a reduced model without HER2 expression, whereas all other covariates remain the same (a 2 degree-of-freedom test).

e

Per 100-unit increase.

f

Odds ratio from the logistic regression model used for overall response.